Standout Papers
Citation Impact
Citing Papers
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
The Metabolic Syndrome and Inflammation
2004
Abdominal obesity and metabolic syndrome
2006 StandoutNature
Which are the Best Biological Markers of the Antiphospholipid Syndrome?
2000
INR calibration of Owren-type prothrombin time based on the relationship between PT% and INR utilizing normal plasma samples
2004 StandoutNobel
Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
2006 Standout
Psoriasis
2009 Standout
Prothrombotic Coagulation Abnormalities Preceding the Hemolytic–Uremic Syndrome
2002
Modulation of the fibrinolytic system by major peripheral ischemia
1994
Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation
2004
Mechanisms linking obesity with cardiovascular disease
2006 StandoutNature
A critical review of the relationship between impaired fibrinolysis and myocardial infarction
1991
TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction
2004 StandoutNobel
The metabolic syndrome
2010 Standout
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
Prevention of venous thromboembolism after acute ischemic stroke
2005
Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk
2003
Thrombin‐activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system
2003
Anti-phosphatidylethanolamine (aPE) Antibodies: a Survey
2000
Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis
1998
Heritability of features of the insulin resistance syndrome in a community‐based study of healthy families
2002
Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome
2005 Standout
Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris
1995 Standout
Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance
2000
Psoriasis
2021 Standout
Changes of the hemostatic network in critically ill patients-Is there a difference between sepsis, trauma, and neurosurgery patients?
2000
Angiogenesis in cancer and other diseases
2000 StandoutNature
The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome
1995 Standout
Angiogenesis in health and disease
2003 Standout
Changes in International Normalized Ratio (INR) and Model for Endstage Liver Disease (MELD) Based on Selection of Clinical Laboratory
2007
Concurrent expression of erythroid and renal aquaporin CHIP and appearance of water channel activity in perinatal rats.
1993 StandoutNobel
The Fibrinolytic System of the Vessel Wall and Its Role in the Control of Thrombosis
1990
The metabolic syndrome
2005 Standout
Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide.
1996
Tissue Plasminogen Activator Contributes to the Late Phase of LTP and to Synaptic Growth in the Hippocampal Mossy Fiber Pathway
1998 StandoutNobel
A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology†
2007
The Antiphospholipid Syndrome
2002 Standout
11 The molecular genetics of familial venous thrombosis
1994
Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a
1997 Standout
Resistance to Activated Protein C as a Basis for Venous Thrombosis
1994 Standout
Anticoagulants for acute ischaemic stroke
2008
Polycystic Ovary Syndrome
2005 Standout
Impaired fibrinolysis in coronary artery disease
1988
Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk
2004
Differential growth state‐dependent regulation of plasminogen activator inhibitor type‐1 expression in senescent IMR‐90 human diploid fibroblasts
1995
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.
1991
Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List
2008 Standout
The metabolic syndrome—a new worldwide definition
2005 Standout
Transgenic mouse models in angiogenesis and cardiovascular disease
2000
Cyclosporine
1989 Standout
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
2001 Standout
World distribution of factor V Leiden
1995 Standout
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
Inflammation, Atherosclerosis, and Coronary Artery Disease
2005 Standout
The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
1992 Standout
Biochemical and biological aspects of the plasminogen activation system
1990
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
1994 Standout
Obesity is associated with macrophage accumulation in adipose tissue
2003 Standout
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study
2004
The pathogenesis of atherosclerosis: a perspective for the 1990s
1993 StandoutNature
The plasminogen activator system in women with polycystic ovary syndrome
1998
Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays
2004
Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies.
1996
Plasminogen activator inhibitors
1987
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group.
1993
High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women
1998
Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss
2005 Standout
PAI-1 and the Metabolic Syndrome
2006
Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1).
1989
Regulation of the endothelial cell urokinase-type plasminogen activator receptor. Evidence for cyclic AMP-dependent and protein kinase C-dependent pathways.
1993 StandoutNobel
Relative Contribution of Insulin and Its Precursors to Fibrinogen and PAI-1 in a Large Population With Different States of Glucose Tolerance
1999
Type 2 diabetes: principles of pathogenesis and therapy
2005 Standout
Medical Perspective Antiphospholipid Antibodies, Thrombosis and Atherosclerosis in Systemic Lupus Erythematosus: a Unifying 'Membrane Stress Syndrome' Hypothesis
1994
THROMBOEMBOLIC COMPLICATIONS AND HAEMOSTATIC CHANGES IN CYCLOSPORIN-TREATED CADAVERIC KIDNEY ALLOGRAFT RECIPIENTS
1985
Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response.
1989
Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke
2007
Hemostatic Activation and Outcome After Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke
2006
Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension.
1990
Prophylaxis of Thrombotic and Embolic Events in Acute Ischemic Stroke With the Low-Molecular-Weight Heparin Certoparin
2005
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome
2000 Standout
Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
2000
Tissue-type plasminogen activator binding to human endothelial cells. Evidence for two distinct binding sites.
1988
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
1993 Standout
Clearance of psoriasis with low dose cyclosporin.
1986
Evidence for reduced fibrinolytic activity in unstable angina at rest. Clinical, biochemical, and angiographic correlates.
1991
Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
1990 StandoutNobel
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
1993 Standout
Coronary Plaque Disruption
1995 Standout
Obesity is associated with macrophage accumulation in adipose tissue
2003 Standout
Deep venous insufficiency: The relationship between lysis and subsequent reflux
1993
The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke
1997 Standout
Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials.
1993
Development of a Genotype 325–Specific proCPU/TAFI ELISA
2003
Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors
2000
Impaired fetal erythrocytes' filterability: relationship with cell size, membrane fluidity, and membrane lipid composition
1992
Thromboembolic Disease – Critical Evaluation of Laboratory Investigation
1992
Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.
1988
Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation
2003
WHICH PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODY SHOULD BE TREATED AND HOW?
1993
Fibrinolytic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris
1996
C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men
1999 Standout
Works of M.F. Aillaud being referenced
Five novel mutations located in exons III and IX of the protein C gene in patients presenting with defective protein C anticoagulant activity
1993
Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome
2003
The plasminogen activator inhibitor-1 −675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study
2003
Prévention des thromboses veineuses profondes des membres inférieurs par une fraction d'héparine de très bas poids moléculaire (CY 222) chez des patients porteurs d'une hémiplégie secondaire à un infarctus cérébral: étude pilote randomisée (30 patients)
1990
Fibrinolytic and inflammatory processes in pleural effusions
1995
Unfading acral microlivedo
1991
Antiphosphatidylethanolamine Antibodies in Systemic Lupus Erythematosus
1993
Metabolic Determinants Are Much More Important Than Genetic Polymorphisms in Determining the PAI-1 Activity and Antigen Plasma Concentrations
1998
Clearance of Tissue Plasminogen Activator (TPA) and TPA/Plasminogen Activator Inhibitor Type 1 (PAI-1) Complex
1997
Correction by insulin added in vitro of abnormal membrane fluidity of the erythrocytes from Type 1 (insulin-dependent) diabetic patients
1986
Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe
2002
Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C and in erythrocyte sedimentation rate with age.
1986
Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions
1984
Multicenter Evaluation of Lyophilized and Deep-frozen Plasmas for Assignment of the International Normalized Ratio
1999 StandoutNobel
Increase in plasma thrombomodulin in systemic lupus erythematosus with antiphospholipid antibodies
1992
Fibrinolysis in insulin dependent diabetic patients with or without nephropathy
1992
Influence of Three Types of Automated Coagulometers on the International Sensitivity Index (ISI) of Rabbit, Human, and Recombinant Human Tissue Factor Preparations
1999 StandoutNobel
Plasma reactivity to hexagonal II phase phosphatidylethanolamine is more frequently associated with lupus anticoagulant than with antiphosphatidylethanolamine antibodies.
1993
Daytime Fluctuations of Plasminogen Activator Inhibitor 1 (PAI-1) in Populations with High PAI-1 Levels
1992
Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis
1987
Increased PA-Inhibitor Levels in the Postoperative Period – No Cause-Effect Relation with Increased Cortisol
1985